All In Biotech

Drug Trial Radar · NCT05641272

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

Prospective, Randomised, DBPC Clinical Trial to Evaluate the Efficacy and Safety of Polymerized and Mannan Conjugated Allergen Extract of Dermatophagoides for the Treatment of Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma

Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Nov 1, 2023

Primary completion

Jun 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Inmunotek S.L.Industry
Sponsor type
Industry
Collaborators
LAT Research; Xolomon Tree S.L.
First posted
Dec 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic rhinitis/rhinoconjunctivitis with or without asthma. The main objective of the clinical trial is to evaluate the clinical efficacy of the investigational medicinal product, administered sublingually, compared to placebo for the treatment of moderate-severe rhinitis/rhinoconjunctivitis with or without mild to moderate asthma and controlled using the Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (R-CSMS).

Conditions

  • Allergic Rhinitis
  • Allergic Asthma
  • Allergic Rhinoconjunctivitis
  • Allergy to House Dust Mite

Interventions

  • 3,000 MM09Biological

    Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 3.000 UTm/mL for sublingual immunotherapy.

  • 9,000 MM09Biological

    Allergoid (Dermatophagoides pteronyssinus and Dermatophagoides farinae)-mannan conjugates (MM09) at 9.000 UTm/mL for sublingual immunotherapy.

  • Placebo sublingualOther

    The same solution, presentation, method of administration, frequency, and duration as the active treatment, but without active ingredients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rhinitis/rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fundación CIDEA

    Buenos Aires, Paraguay, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.